2000/112/EC: Commission Decision of 14 January 2000 detailing the distribution between antigen banks of antigen reserves established within the framework of the Community action concerning reserves of foot-and-mouth disease vaccines and amending Commission Decisions 93/590/EC and 97/348/EC (notified under document number C(2000) 1) (Text with EEA relevance)
8. 2. 2000 EN Official Journal of the European Communities L 33/21 COMMISSION DECISION of 14 January 2000 detailing the distribution between antigen banks of antigen reserves established within the frame- work of the Community action concerning reserves of foot-and-mouth disease vaccines and amending Commission Decisions 93/590/EC and 97/348/EC (notified under document number C(2000) 1) (Text with EEA relevance) (2000/112/EC) THE COMMISSION OF THE EUROPEAN COMMUNITIES, Having regard to the Treaty establishing the European Community, Having regard to Council Decision 91/666/EEC of 11 December 1991 establishing Community reserves of foot-and- mouth disease vaccines (1), as last amended by Council Decision 1999/762/EC (2), and in particular Articles 7 thereof, Whereas: (1) (2) (3) (4) (5) in accordance with Article 7 of Council Decision 91/ 666/EEC the Commission shall adopt detailed arrange- ments in particular with regard to the distribution of antigen reserves between antigen banks; antigens within Article 3 of Commission Decision 93/590/EC of 5 November 1993, for the purchase of foot-and-mouth the framework disease Community action concerning reserves of foot-and- mouth disease vaccines (3) as last amended by Decision 95/471/EC (4), makes provisions for the antigen to be stored at three specified locations; the of Commission Decision 97/348/EC of 23 May 1997 for the purchase by the Community of foot-and-mouth disease antigens and for the formulation, production, bottling and distribution of vaccines against foot-and- the distribution of newly mouth disease (5), details purchased antigen to designated antigen banks; by Decision 2000/111/EC (6) the Commission desig- nated Merial SAS, Pirbright, United Kingdom as a third antigen bank and made provisions for the transfer of antigen from a bank no longer designated; as regards the quantities and types of antigen stored at designated antigen banks account must be taken of the new situation and for the sake of clarity these quantities (6) (7) and types of antigen should be listed for each designated antigen bank according to the new situation; the provisions of Article 3 of Decision 93/590/EC and of Article 5 of Decision 97/348/EC are no longer adapted to the new situation and should be repealed; the measures provided for in this Decision are in accord- ance with the opinion of the Standing Veterinry Committee, HAS ADOPTED THIS DECISION: Article 1 The quantities and types of antigen stored within the frame- work of Community reserves of foot-and-mouth disease antigen shall be distributed between designated antigen banks in accordance with the provisions in the Annex. Article 2 1. 2. Article 3 of Decision 93/590/EC is repealed. Article 5 of Decision 97/348/EC is repealed. Article 3 This Decision shall apply from 1 February 2000. This Decision is addressed to the Member States. Article 4 Done at Brussels, 14 January 2000. For the Commission David BYRNE Member of the Commission (1) OJ L 368, 31. 12. 1991, p. 21. (2) OJ L 301, 24. 11. 1999, p. 6. (3) OJ L 280, 13. 11. 1993, p. 33. (4) OJ L 269, 11. 11. 1995, p. 29. (5) OJ L 148, 6. 6. 1997, p. 27. (6) See page 19 of this Official Journal. L 33/22 EN Official Journal of the European Communities 8. 2. 2000 ANNEX EUROPEAN ANTIGEN BANK Designated antigen banks EUROPEAN ANTIGEN BANK IZP Brescia LNPB Lyon Merial S. A. S. Pirbright Antigen type/subtype Quantity (1) (× 1 000 000) Quantity (1) (× 1 000 000) Quantity (1) (× 1 000 000) Quantity (1) (× 1 000 000) total per antigen O1 — Manissa O1 — BFS A24 — Cruzeiro A22 — Iraq C1 — Noville ASIA1 — Shamir Quantity (1) (× 1 000 000) total per site 2,5 — — 2,5 2,5 2,5 2,5 2,5 2,5 3,9 — — — 2,5 2,5 — 2,5 2,5 5,0 5,0 5,0 6,4 5,0 5,0 10,0 11,4 10,0 31,4 (1) Quantity in vaccine equivalent antigen doses